Updates on Cancer Treatment 2015
DOI: 10.5772/60794
|View full text |Cite
|
Sign up to set email alerts
|

A Close Look at Neutropenia among Cancer Patients — Risk Factor and Management

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
4
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 42 publications
0
4
0
Order By: Relevance
“…67 (39,88) 26 (15,48) 20 (11,9) 24 (14,29) 11 (6,55) 20 (11,9) Chemotherapy The CISNE scores effectively predicted febrile neutropenia complications resulting from chemotherapy treatment of a solid malignancy with an AUROC of 0.893 (CI 95% 0.829-0.95; p = 0.03), whereas the MASCC scores with an AUROC of 0.77 (CI 95% 0.68-0.86; p = 0,04). Therefore, CISNE scores were found to be signi cantly better at predicting complications than MASCC scores in solid malignancy.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…67 (39,88) 26 (15,48) 20 (11,9) 24 (14,29) 11 (6,55) 20 (11,9) Chemotherapy The CISNE scores effectively predicted febrile neutropenia complications resulting from chemotherapy treatment of a solid malignancy with an AUROC of 0.893 (CI 95% 0.829-0.95; p = 0.03), whereas the MASCC scores with an AUROC of 0.77 (CI 95% 0.68-0.86; p = 0,04). Therefore, CISNE scores were found to be signi cantly better at predicting complications than MASCC scores in solid malignancy.…”
Section: Resultsmentioning
confidence: 99%
“…These ndings showed a difference in the prevalence of tumors in our study location, because as the national referral hospital we received many end-stage cancer patients with different types of tumor distribution. [14,15] In hematologic malignancy subjects, 87.67% of patients had non-Hodgkin's lymphoma. We excluded patients with acute leukemia because febrile neutropenia in acute leukemia patients, according to the IDSA guidelines, are in the high-risk category, regardless of their MASCC scores.…”
Section: Discussionmentioning
confidence: 99%
“…Immunosuppressive/cytotoxic chemotherapies target the rapidly dividing cells of the body and produce dose-dependent toxicity on cell production, protein synthesis, bone marrow, and cell survival, and their mechanism of drug-inducing immunological reaction results in cell destruction and hence leads to neutropenia. [ 7 8 ]…”
Section: Introductionmentioning
confidence: 99%
“…Hassan et al reported that the incidence of neutropenia was predominant among individuals aged 65 years or more compared to younger than 65 years of age[39] and explained his findings by the fact that Neutropenia is more common among the older age group (65 years and more) because their ability to produce mature neutrophil is reduced and recommend to reduce the dose of chemotherapy and the administration of granulocyte colony-stimulating factor should be increased in older age group. ALL and AA are mainly diseases of young age group and AML seen in younger age group of Iraqi population, those three forms the majority of cases in this study.…”
mentioning
confidence: 99%